MIB-1 labelling index is an independent prognostic marker in primary breast cancer

Jansen, R. L. H.; Hupperets, P.; Arends, Jan Willem; Joosten-Achjanie, S. R.; Volovics, A.; Schouten, H.; Hillen, H.F.P.

doi:10.1038/bjc.1998.515

Cited by 90 publications

(45 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most frequently used antibody of this kind is MIB-1, which was first reported by Cattoretti et al in 1992. 25 The proliferative activity determined by MIB-1 has generally confirmed the findings obtained with the original Ki-67 antibody; that is, correlation with tumour grade, [30][31][32] clinical course, [33][34][35][36] and other methods for the evaluation of growth rate. 30 31 37 "A major drawback of the prototypic Ki-67 antibody is that it can be used on frozen sections only" It is expected that the application of the various Ki-67 equivalent antibodies should produce similar staining results, although to our knowledge comparisons of the qualitative and quantitative staining properties of Ki-67 equivalent antibodies under standardised conditions have not been reported previously.…”

supporting

confidence: 60%

Comparison of Ki-67 equivalent antibodies

Lindboe¹,

Torp²

2002

Journal of Clinical Pathology

View full text Add to dashboard Cite

Aims: To compare commercially available Ki-67 equivalent antibodies with regard to qualitative and quantitative immunohistochemical staining characteristics. Methods: The following antibodies were used: monoclonal MIB-1 (Immunotech), monoclonal MM1 (Novocastra), polyclonal NCL-Ki-67p (Novocastra), and polyclonal Rah Ki-67 (Dako). All immunostainings were evaluated in squamous epithelium from formalin fixed and paraffin wax embedded pharyngeal tonsils. Labelling indices (LIs) were recorded twice to test their reproducibility. Results: By application of all four antibodies the nuclear staining could be either diffuse, granular, or a combination of both (classified as granular in this study). The diffuse pattern generally showed a strong or moderate staining intensity, whereas the granular pattern displayed a continuum from strong to very weak, making it difficult to discriminate between positive and negative nuclei. The diffuse staining pattern was seen in approximately 59% of the nuclei with the MIB-1 antibody and in 35-45% when the other antibodies were used. The following mean LIs were recorded: MIB-1, 31%; NCL-Ki-67p, 21%; Rah Ki-67, 17%; and MM1, 14%. The reproducibility was excellent for all four antibodies, with the mean of differences between the two runs of counts ranging from 1.1% to 1.5%. Conclusions: The four tested Ki-67 equivalent antibodies revealed differences in qualitative and quantitative staining characteristics, which resulted in considerable variations in registered LIs. The MIB-1 antibody appears to have a higher sensitivity for detecting the Ki-67 antigen than the other three tested antibodies. These differences are important to consider when proliferative activity is determined by the Ki-67 LI.

show abstract

supporting

confidence: 60%

Comparison of Ki-67 equivalent antibodies

Lindboe¹,

Torp²

2002

Journal of Clinical Pathology

View full text Add to dashboard Cite

show abstract

“…Out of the 38 evaluable studies for DFS (10 954 patients), subgroup analysis was possible in 15 studies with node-negative patients (3370 patients) (Sahin et al, 1991;Weikel et al, 1991Weikel et al, , 1995Gaglia et al, 1993;Bevilacqua et al, 1996;Brown et al, 1996;Pierga et al, 1996;Railo et al, 1997;Jansen et al, 1998;Clahsen et al, 1999;Harbeck et al, 1999;Rudolph et al, 1999a;Billgren et al, 2002;Trihia et al, 2003;Erdem et al, 2005), in eight with node-positive patients (1430 patients) (Weikel et al, 1991Gaglia et al, 1993;Pierga et al, 1996;Jansen et al, 1998;Billgren et al, 2002;Trihia et al, 2003;Esteva et al, 2004) and in six with untreated nodenegative patients (736 patients) (Sahin et al, 1991;Weikel et al, 1991;Bevilacqua et al, 1996;Railo et al, 1997;Jansen et al, 1998;Harbeck et al, 1999). Regarding OS (9472 patients), of all 35 studies, subgroup analysis was possible in nine studies with nodenegative patients (1996 patients) (Jensen et al, 1995;Weikel et al, 1995;Bevilacqua et al, 1996;Brown et al, 1996;Domagala et al, 1996;Fresno et al, 1997;Rudolph et al, 1999a;Trihia et al, 2003;Erdem et al, 2005), in four with node-positive patients (857 patients) Domagala et...…”

Section: Characteristics Of the Studiesmentioning

confidence: 99%

Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients

et al. 2007

View full text Add to dashboard Cite

The Ki-67 antigen is used to evaluate the proliferative activity of breast cancer (BC); however, Ki-67's role as a prognostic marker in BC is still undefined. In order to better define the prognostic value of Ki-67/MIB-1, we performed a meta-analysis of studies that evaluated the impact of Ki-67/MIB-1 on disease-free survival (DFS) and/or on overall survival (OS) in early BC. Sixty-eight studies were identified and 46 studies including 12 155 patients were evaluable for our meta-analysis; 38 studies were evaluable for the aggregation of results for DFS, and 35 studies for OS. Patients were considered to present positive tumours for the expression of Ki-67/MIB-1 according to the cut-off points defined by the authors. Ki-67/MIB-1 positivity is associated with higher probability of relapse in all patients (HR ¼ 1.93 (95% confidence interval (CI): 1.74 -2.14); Po0.001), in node-negative patients (HR ¼ 2.31 (95% CI: 1.83 -2.92); Po0.001) and in node-positive patients (HR ¼ 1.59 (95% CI: 1.35 -1.87); Po0.001). Furthermore, Ki-67/MIB-1 positivity is associated with worse survival in all patients (HR ¼ 1.95 (95% CI: 1.70 -2.24; Po0.001)), node-negative patients (HR ¼ 2.54 (95% CI: 1.65 -3.91); Po0.001) and node-positive patients (HR ¼ 2.33 (95% CI: 1.83 -2.95); Po0.001). Our meta-analysis suggests that Ki-67/ MIB-1 positivity confers a higher risk of relapse and a worse survival in patients with early BC.

show abstract

“…The Ki-67 labeling index (percentage of positive nuclei) is often correlated with the clinical course of the disease. 12,22 The MIB-1 monoclonal antibody (MIB-1) directed against this antigen produces a cross-reaction in frozen and paraffinembedded feline tissue sections. 13 The few studies on the determination of cell proliferation activity of canine and feline mammary tumors by the immunohistochemical detection of Ki-67 antigen have produced contradictory results.…”

mentioning

confidence: 99%

MIB-1 Labeling Index in Feline Dysplastic and Neoplastic Mammary Lesions and Its Relationship with Postsurgical Prognosis

et al. 2002

View full text Add to dashboard Cite

Abstract. Samples from feline normal, dysplastic, and neoplastic mammary tissues were used to investigate the usefulness of MIB-1 labeling index (MIB-1 I) as a prognostic indicator. Forty-eight queens bearing invasive carcinomas were included in a 2-year follow-up study. Mammary lesions were classified according to the World Health Organization system, and invasive carcinomas were further graded on the basis of the degree of tubule formation, the degree of nuclear and cellular pleomorphism, and mitotic count. Additional sections were immunostained using MIB-1 antibody, and MIB-1 I was expressed as a percentage of positive nuclei. In normal mammary gland tissues, the mean MIB-1 I was Ͻ1%. A low proliferation rate was found in all mammary adenosis and in situ carcinomas, and the highest rates were observed in feline mammary hypertrophy and invasive carcinomas. Twenty-one (43.7%) of the queens bearing invasive carcinomas were still alive at the end of the trial, and 27 (56.2%) had died. The MIB-1 I was not significantly correlated with clinical outcome, age, histologic type, or grading of the tumors, but a borderline correlation was observed with invasion of lymphatic vessels. Univariate analysis showed that high MIB-1 I was also not associated with decreased overall survival, whereas the grading system of the tumors had high predictive value (P ϭ 0.0040) for postsurgery survival. The lack of correlation between MIB-1 I and postsurgery survival suggests that this marker alone is not sufficient to determine a correct prognosis in feline mammary carcinomas, even if it is a useful proliferation marker.

show abstract

MIB-1 labelling index is an independent prognostic marker in primary breast cancer

Cited by 90 publications

References 31 publications

Comparison of Ki-67 equivalent antibodies

Comparison of Ki-67 equivalent antibodies

Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients

MIB-1 Labeling Index in Feline Dysplastic and Neoplastic Mammary Lesions and Its Relationship with Postsurgical Prognosis

Contact Info

Product

Resources

About